Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2015
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:associatedWith |
gptkb:Abilify_Maintena
|
| gptkbp:ATCCode |
gptkb:N05AX12
|
| gptkbp:CASNumber |
1258822-89-9
|
| gptkbp:chemicalFormula |
C25H27Cl2N3O4
|
| gptkbp:dosageForms |
1064 mg
441 mg 662 mg 882 mg |
| gptkbp:drugClass |
antipsychotic medication
|
| gptkbp:form |
extended-release injectable suspension
|
| gptkbp:genericName |
gptkb:aripiprazole_lauroxil
|
| gptkbp:halfLife |
29 to 34 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aristada
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Alkermes
|
| gptkbp:mechanismOfAction |
serotonin 5-HT2A receptor antagonist
dopamine D2 receptor partial agonist |
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
anxiety
weight gain insomnia injection site pain akathisia |
| gptkbp:usedFor |
schizophrenia
|
| gptkbp:bfsParent |
gptkb:Alkermes
|
| gptkbp:bfsLayer |
7
|